Tricyclic inhibitors of poly(ADP-ribose)polymerase

The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular acti...

Full description

Saved in:
Bibliographic Details
Main Authors Maung, Jack, Shen, Wang, Zhang, Aimin, Zheng, Xiaoling
Format Patent
LanguageEnglish
Published 15.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
AbstractList The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
Author Zheng, Xiaoling
Shen, Wang
Zhang, Aimin
Maung, Jack
Author_xml – fullname: Maung, Jack
– fullname: Shen, Wang
– fullname: Zhang, Aimin
– fullname: Zheng, Xiaoling
BookMark eNrjYmDJy89L5WQwCinKTK5MzslMVsjMy8hMyizJLypWyE9TKMjPqdRwdAnQLcpMyi9O1QTxc1OLEotTeRhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJfGiwoaGRiYWBobGTkTExagDHiC3l
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US11248013B2
GroupedDBID EVB
ID FETCH-epo_espacenet_US11248013B23
IEDL.DBID EVB
IngestDate Fri Jul 19 13:21:17 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US11248013B23
Notes Application Number: US201916666307
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220215&DB=EPODOC&CC=US&NR=11248013B2
ParticipantIDs epo_espacenet_US11248013B2
PublicationCentury 2000
PublicationDate 20220215
PublicationDateYYYYMMDD 2022-02-15
PublicationDate_xml – month: 02
  year: 2022
  text: 20220215
  day: 15
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies Rakovina Therapeutics Inc
RelatedCompanies_xml – name: Rakovina Therapeutics Inc
Score 3.3837192
Snippet The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are...
SourceID epo
SourceType Open Access Repository
SubjectTerms ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
Title Tricyclic inhibitors of poly(ADP-ribose)polymerase
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220215&DB=EPODOC&locale=&CC=US&NR=11248013B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhT1Dedis4PKkjRh2LXph8vRewXQ9hWXCt7G02bYkXaslZk_95L6Zwv-nZJ4HIJ3GdydwC3RNWZimaCRDMlkYjJZITSREpj3ZTjLNYSg-cOT6b6OCLPC23Rg_dNLkxbJ_SrLY6IHJUgvzetvK62QSy3_VtZP9Acp8pHP7RcsfOOFYWrMNG1LS-YuTNHdBwrmovTFwvNCl4oRbVRXO-gGW1wbvBebZ6VUv1WKf4h7AaIrWiOoMeKAew7m85rA9ibdA_eCHa8Vx-DEqLIWidIn5AXbznNeZ8cocyEqvxY3z25gbTKaVmzez7moaaancCN74XOWMLNlz8nXUbzLZ3qKfSLsmBnIBjUoJSo6D2YMWGUUKZSotHRiBE5U1JyDsO_8Qz_W7yAA35r_BvySLuEfrP6ZFeoZRt63V7PN_mvgdI
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhTnG86FZ1fFaToQ7Ef6bqXIq7dmLp2xXWyt9K0KVakHWtF9u-9lM75om-XBC6XwH0mdwdwTbQu09BMkGiiRhLpMRmhOJLisNuTwyTUI4PnDjtudzQjT3N93oD3dS5MVSf0qyqOiBwVIb-XlbxebIJYdvW3srijKU7l90PftMXaO1ZVrsJEu28OvIk9sUTLMmdT0X0x0azghVK0PorrLTSxDc4Ng9c-z0pZ_FYpwz3Y9hBbVu5Dg2VtaFnrzmtt2HHqB28Ea94rDkD1UWStIqRPSLO3lKa8T46QJ8Ii_1jdPNietExpXrBbPuahpoIdwtVw4FsjCTcPfk4azKYbOrUjaGZ5xo5BMKhBKdHQe-iFhFFCmUaJThWFETlRY3ICnb_xdP5bvITWyHfGwfjRfT6FXX6D_Euyop9Bs1x-snPUuCW9qK7qGzuthMU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Tricyclic+inhibitors+of+poly%28ADP-ribose%29polymerase&rft.inventor=Maung%2C+Jack&rft.inventor=Shen%2C+Wang&rft.inventor=Zhang%2C+Aimin&rft.inventor=Zheng%2C+Xiaoling&rft.date=2022-02-15&rft.externalDBID=B2&rft.externalDocID=US11248013B2